Dr. Reddys Laboratories Ltd.

Galena Biopharma and Dr Reddys Laboratories have entered into strategic partnership for NeuVax in India. NeuVax is the immunodominant nonapeptide derived from the HER2 protein, a target for therapeutic intervention in breast cancer.

Galena will license the commercial rights for NeuVax (nelipepimut-S) to Dr Reddys and the India based pharmaceutical company will also lead the development of NeuVax in Gastric Cancer, significantly expanding the potential addressable patient population. Meanwhile, Galena will receive development and sales milestones, as well as double-digit royalties on net sales.

Galena Biopharma is a biopharmaceutical company commercializing and developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. Dr Reddys Laboratories is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.